Oral anticoagulant prescription in hospitalized atrial fibrillation patients increased significantly from 35.63% in 2010-2012 to 61.18% in 2019-2021, driven by a rise in direct oral anticoagulant use.
Observational (n=3,067)
No
What are the temporal trends in antithrombotic therapy prescription patterns for hospitalized patients with atrial fibrillation?
Real-world prescription of oral anticoagulants and DOACs for atrial fibrillation has gradually increased over time, reflecting slow implementation of guidelines.
Absolute Event Rate: 61.18% vs 35.63%
p-value: p=<0.0001
BACKGROUND: Since 2010, the European Society of Cardiology has extended prescription criteria for oral antithrombotic therapy (OAT) in atrial fibrillation (AF). Direct oral anticoagulants (DOACs) were upgraded from an IIAa recommendation in 2012 to an IA in 2016. In real-world scenarios, however, OAC prescription is still suboptimal, mainly for DOACs. AIM: To evaluate OAT temporal prescription patterns in a cohort of patients hospitalized with AF in a Cardiology Department. METHODS: A retrospective observational study was conducted on a cohort of hospitalized patients in a secondary setting (Trapani, Italy) from 2010 to 2021 with AF as the main or secondary diagnosis. For 4089 consecutive patients, the variables extracted from the Cardiology department database were: Sex, age, time of hospitalization, antithrombotic therapy (warfarin, acenocoumarol, apixaban, dabigatran, edoxaban, rivaroxaban, aspirin, clopidogrel, other antiplatelet agents, low molecular weight heparin, and fondaparinux), diagnosis at discharge and used resources. Basal features are presented as percentage values for categorized variables and as mean +/- SD for categorized once. RESULTS: < 0.0001). CONCLUSION: Real-world patients with AF are elderly and affected by cardiovascular and non-cardiovascular diseases. The percentage of patients on OAT and DOACs increased. These data suggest a slow, gradual guidelines implementation process.
Abrignani et al. (Wed,) conducted a observational in Atrial fibrillation (n=3,067). Oral antithrombotic therapy (OAT) / DOACs vs. Historical practice (2010-2012) was evaluated on Oral anticoagulant (OAC) prescription rate (p=<0.0001). Oral anticoagulant prescription in hospitalized atrial fibrillation patients increased significantly from 35.63% in 2010-2012 to 61.18% in 2019-2021, driven by a rise in direct oral anticoagulant use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: